Sumitomo Dainippon Pharma

Aug. 01, 2019Finances

Posted Conference Call for Q1 FY2019 [Webcast]
Jul. 31, 2019 (PDF/123KB)R&D

Sumitomo Dainippon Pharma Submits New Drug Application for Approval of Manufacturing and Marketing for Lurasidone in Japan for the Treatment of Schizophrenia and Bipolar Depression
Jul. 31, 2019 (PDF/173KB)R&D

Sunovion Announces Acceptance by the U.S. FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder
Jul. 29, 2019 (PDF/582KB)Finances

Presentation Material (First Quarter Financial Results for FY2019)
Jul. 29, 2019 (PDF/457KB)Finances

Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2020

Other Notices

IR Library